A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Recruiting

Phase 2

Phase 3

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia ConditionsA Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

Sponsor:

Takeda

Code:

NCT05816382

Conditions

Narcolepsy Type 1

Eligibility Criteria

Sex: All

Age: 16 - 70

Healthy Volunteers: Not accepted

Interventions

TAK-861

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Takeda on 2024-09-25.